Angiotropic large cell lymphoma (ALCL): Morphological, immunohistochemical and genotypic studies with analysis of previous reports

Domizio, Paola; Hall, P. A.; Cotter, Finbarr E.; Amiel, Stephanie A.; Tucker, J.; Besser, G. M.; Levison, David A.

doi:10.1002/hon.2900070303

Cited by 135 publications

(77 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a review of 86 cases of intravascular large B-cell lymphoma, there was a median survival of 5 months from the date of clinical presentation. 20 Prolongation of survival has been reported in patients with intravascular large B-cell lymphoma who are treated with chemotherapy. 21 In a review of 35 patients who received chemotherapy, 54% had a complete remission.…”

Section: Discussionmentioning

confidence: 99%

Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm

et al. 2005

View full text Add to dashboard Cite

We report the clinicopathological features of two cases of intravascular large B-cell lymphoma involving cutaneous hemangiomas. The cases were identified from the consultation files of two of the authors. Both patients were women, 64 and 55 years of age, who presented with long-standing cutaneous hemangiomas of the posterior scalp and left shoulder, respectively. The lesions were brought to medical attention by an increase in size and change in color. Biopsies and immunohistochemical evaluation of the hemangiomas revealed extensive involvement by intravascular large B-cell lymphoma. The neoplastic cells were diffusely positive for CD20 in both cases and negative for CD3, pan-cytokeratin (AE1/AE3), epithelial membrane antigen, S-100, Factor VIII-related antigen, CD34 and CD31. Disease was limited to the hemangiomas in both patients. Treatment consisted of chemotherapy (both patients) and adjuvant radiation therapy (one patient). One patient had a recurrence of disease 33 months after initial diagnosis, leading to an autologous stem cell transplant. The other patient is without evidence of disease 27 months after initial diagnosis. Although this is a rare neoplasm, it is important to consider intravascular large B-cell lymphoma in the differential diagnosis of vascular lesions containing intravascular neoplastic cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The absence of IVL in traditional sites of lymphoma presentation makes accurate and timely diagnosis difficult. In previous reports, around half of patients have been diagnosed post mortem, 2 and repeated biopsies of skin, kidney, and bone marrow are often necessary for the diagnosis of this type of lymphoma. 3,4 Left untreated, IVL is uniformly fatal.…”

Section: Introductionmentioning

confidence: 99%

“…Steroids generally provided only transient improvement. 2 Most therapeutic regimens were ineffective, with a median survival of several months from the date of clinical presentation. 4,5 Recently, anthracycline-containing chemotherapy has been reported to improve clinical outcomes of patients with IVL.…”

Section: Introductionmentioning

confidence: 99%

Sustained Remission after Rituximab-containing Chemotherapy for Intravascular Large B-cell Lymphoma

Shimada

Kosugi

Narimatsu

et al. 2008

J Clin Exp Hematopathol

View full text Add to dashboard Cite

Intravascular large B-cell lymphoma (IVL) is rare aggressive disseminated lymphoma associated with poor outcomes. Rituximab is a novel molecular agent that can reportedly improve outcomes for patients with diffuse large B-cell lymphoma. However, the safety and efficacy of rituximab in patients with IVL are unclear. A 76-year-old woman was hospitalized due to altered consciousness, fever and respiratory abnormalities. Definitive diagnosis of IVL was obtained following repeated biopsies of bone marrow. The patient received chemotherapy consisting of cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP), and achieved complete remission after 3 courses of treatment. She has remained in complete remission for over 3 years after diagnosis. This report suggests that rituximab-containing regimens could be safe and effective for elderly patients with IVL. 〔J Clin Exp Hematopathol 48(1) : 25-28, 2008〕

show abstract

“…Furthermore, IVLBCL often can be an aggressive disease and results in severe outcomes (Ferreri et al 2004). Thus, the diagnosis of IVLBCL had been often made based on postmortem examinations in previous reports (Domizio et al 1989). However, advances in diagnostic technology and the recognition of the disease have increased the diagnostic yield for IVLBCL in recent years.…”

Section: Discussionmentioning

confidence: 99%

Reversible Hypopituitarism Associated with Intravascular Large B-Cell Lymphoma: Case Report of Successful Immunochemotherapy

Sawada

Ishii

Koga

et al. 2016

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of diffuse large B-cell lymphoma. There have been only a limited number of reports regarding pituitary dysfunction associated with IVLBCL. We present a 71-year-old woman with hypopituitarism without any hypothalamic/pituitary abnormalities as assessed by magnetic resonance imaging. She presented with edema, abducens palsy, and elevated levels of lactate dehydrogenase and soluble interleukin-2 receptor. Provocative testing showed that the peaks of luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone and adrenocorticotropic hormone were evoked to normal levels by simultaneous administration of luteinizing hormone-releasing hormone, thyrotropin-releasing hormone and corticotropin-releasing hormone, but the responses of these four pituitary hormones showed a delayed pattern. She was diagnosed with IVLBCL with cerebrospinal invasion by pathological findings of the bone marrow, skin, and cerebrospinal fluid. She achieved hematological remission after immunochemotherapy. Pituitary function was also restored without hormonal replacement, and the improvement of the pituitary function was confirmed by dynamic testing. We reviewed the literature with respect to hypopituitarism associated with IVLBCL. There were less than 20 case reports and most of the patients died. Endocrinological course was described in only two cases, and both of them required hormonal supplementation. To our knowledge, this is the first case of hypopituitarism induced by IVLBCL that was successfully managed by immunochemotherapy alone. This case suggests that early diagnosis and treatment of IVLBCL might improve anterior pituitary function and enable patients to avoid hormone replacement therapy.

show abstract

Angiotropic large cell lymphoma (ALCL): Morphological, immunohistochemical and genotypic studies with analysis of previous reports

Cited by 135 publications

References 32 publications

Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm

Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm

Sustained Remission after Rituximab-containing Chemotherapy for Intravascular Large B-cell Lymphoma

Reversible Hypopituitarism Associated with Intravascular Large B-Cell Lymphoma: Case Report of Successful Immunochemotherapy

Contact Info

Product

Resources

About